5 completed, 3 terminated, 1 active not recruiting, 1 withdrawn. 6 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Terminated 3 |
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Withdrawn 1 |
Follow padeliporfin: new trials by email Literature Review of padeliporfin trials Research Report on padeliporfin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study padeliporfin VTP - Transitional Cell Cancer of Renal Pelvis and Ureter | Phase 3 | Active not recruiting | Steba Biotech S.A. | 89 | 2021-03-22 | 2026-07-30 |
| Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer TOOKAD® - Localized Prostate Cancer | Phase 3 | Withdrawn | Steba Biotech S.A. | 2020-03-31 | 2020-11-13 | |
| Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. TOOKAD Soluble 4 mg/kg - Localized Prostate Cancer | Phase 2 | Completed | Steba Biotech S.A. | 50 | 2017-10-02 | 2026-09-10 |
| Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer TOOKAD® Soluble - Prostate Cancer | Phase 3 | Completed | Steba Biotech S.A. | 81 | 2013-05-01 | 2016-04-19 |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. TOOKAD® Soluble - Prostate Cancer | Phase 3 | Completed | Steba Biotech S.A. | 413 | 2011-02-01 | 2019-07-11 |
| Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD STAKEL - Macular Degeneration, Choroidal Neovascularization | Phase 2 | Terminated | Steba Biotech S.A. | 10 | 2010-06-01 | 2018-09-17 |
| Study Using WST11 in Patients With Localized Prostate Cancer WST11 - Prostate Cancer | Phase 2 | Completed | Steba Biotech S.A. | 86 | 2009-09-01 | 2015-04-28 |
| Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma WST11 - Cholangiocarcinoma | Phase 2 | Terminated | Steba Biotech S.A. | 8 | 2009-09-01 | 2016-04-18 |
| Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer WST11 - Non-Small Cell Lung Cancer | Phase 2 | Terminated | Steba Biotech S.A. | 3 | 2009-09-01 | 2015-04-28 |
| Study of WST11 in Patients With Localized Prostate Cancer WST11 - Prostate Cancer | Phase 2 | Completed | Steba Biotech S.A. | 42 | 2008-09-01 | 2016-04-19 |
Carcinoma (6) · Genital Neoplasms, Male (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Prostatic Diseases (5) · Prostatic Neoplasms (5) · Urogenital Neoplasms (5) · Genital Diseases, Male (4) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Choroidal Neovascularization (1) · Genital Diseases (1) · Lung Neoplasms (1) · Macular Degeneration (1)
Steba Biotech S.A. (10)
France (7) · United States (4) · United Kingdom (3) · Germany (2) · Netherlands (2) · Spain (2) · Belgium (1) · Canada (1) · Finland (1) · Israel (1) · Italy (1) · Mexico (1) · Panama (1) · Peru (1) · Sweden (1)
Jonathan Coleman, MD (2) · Mark Emberton, Professor (2) · Adrienne Scott, Doctor (1) · Emmanuel Ben Soussan, MD (1) · Francine Behar Cohen, Professor (1) · John Wells, Professor (1) · Jose Arturo Rodriguez Rivera, Dr (1) · Luis Zegarra Montes, Professor (1) · Michel Leroy, MD (1)
PMID 25712310, PMID 25614256, PMID 25786708, PMID 21296274, PMID 24028764, PMID 24841929, PMID 28007457